Number and nature of drug interactions concerning antiretroviral drugs;Estimation du nombre et de la nature des interactions mé dicamenteuses concernant les médicaments antirétroviraux

Journal de Pharmacie Clinique

Volumn 25, Issue 3, 2006, Pages 153-159

  Jurus, V ^a   Bossaert, S ^a   Charpiat, B ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

Antiretroviral drugs; Drug interactions

Indexed keywords

ABACAVIR; ALBENDAZOLE; ALIMEMAZINE TARTRATE; ALTRETAMINE; AMIODARONE; AMPRENAVIR; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METFORMIN EMBONATE; MICROPAKINE; NEVIRAPINE; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DRUG CONTRAINDICATION; DRUG MARKETING; DRUG POTENTIATION; FRANCE; HEALTH CARE PERSONNEL; HUMAN; IN VITRO STUDY; NONHUMAN; PHARMACIST; SCIENTIFIC LITERATURE;

EID: 33749463805     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Auray G, Charpiat B. Programme de formation des étudiants en stage hospitalier à la consultation pharmaceutique: application à la dispensation des antirétroviraux. J Pharm Clin 2000; 19: 231-6.
2. Macchi-Andanson M, Ariagno L, Charpiat B, Leboucher G. Consultation de pharmacie et observance des traitements antirétroviraux: enquête auprès des patients. J Pharm Belg 2001; 56: 69-74.
3. Thésaurus des interactions médicamenteuses - mise à jour n° 2 http://agmed.sante.gouv.fr/htm/10/iam/triam.pdf. Consulté le 20 juillet 2005.
4. e édition. Paris: Édition Vidal, 2005.
5. Dossier du CNHIM. Principales associations d'antirétroviraux dans le traitement des infections à VIH. 2002, n° 5-6.
6. http://www.theriaque.org. Consulté le 20 juillet 2005.
7. De Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42: 223-82.
8. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44: 111-45.
9. Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetics interactions. J Antimicrob Chemother 2005; 56: 1-5.
10. Ouellet D, Hsu A, Qian J, Lamm JE, Cavanaugh JH, Leonard JM, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998; 42: 3107-12.
11. Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoproteine involvement. Clin Pharmacol Ther 2001; 70: 405-14.
12. Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 2001; 51: 591-600.
13. Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002; 36: 827-30.
14. Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003; 37: 1793-6.
15. Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and HIV-infected patients. Eur J Clin Pharmacol 2001; 57: 115-21.
16. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002; 62: 6158-64.
17. Bower M, Powles T, Stebbing J, Thirlwell C. Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide. J Clin Oncol 2005; 23: 1328-9.
18. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004; 64: 7426-31.
19. Nannan Panday VR, Hoetelmans RM, van Heeswijk RP, Meenhorst PL, Inghels M, Mulder JW, et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma-drug-drug interactions with protease inhibitors and a non-nucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol 1999; 43: 516-9.
20. Hardy G, Stanke-Labesque F, Contamin C, Serre-Debeauvais F, Bayle F, Zaoui P, et al. Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report. Eur J Clin Pharmacol 2004; 60: 603-5.
21. Martindale: the complete drug reference. Cederom, version 51. Pharmaceutical Press. Electronic version. Thomson Micromedex. Mise à jour, septembre 2005.
22. re partie: données pharmacocinétiques qualitatives. Medecine 2006; 2: 219-22.
23. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19: 14-9.
24. Lavole A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J. Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 2006; 51: 1-11.
25. Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 1999; 13: 283-4.
26. Teil J, Henry A, Bossaert S, Charpiat B, Chekaoui A, Biron F, et al. Drug interactions between taxanes and antiretroviral agents: report of 2 cases. Fundament Clin Pharmacol 2006; 20: 188; (abstract P259).
27. Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol 2004; 27: 81-4.
28. Parameswaran R, Sweeny C, Einhorn L. Interaction between highly active antiretroviral therapy (HAART) and taxanes: a report of two cases. Meeting: 2002 ASCO annual meeting. Abstract n° 2194.
29. Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 2005; 61: 327-35.
30. Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 2005; 30: 21-37.
31. Cohen JS. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med 2001; 161: 957-64.
32. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005; 331: 263-6.
33. e édition. Paris: Doin éditeurs, 2005.
34. Li Wan Po A. Drug-drug interactions and adverse drug reactions: the bollards and flashing lights syndrome. J Clin Pharm Ther 2005; 30: 97-9.
35. Mille F, Bourdon O, Fontan JE, Brion F. Évaluation de la spécificité d'un système de détection automatisée des interactions médicamenteuses. Act Pharm Biol Clin 2005; 12: 361-8.
36. Smith WD, Hatton RC, Fann AL, Baz MA, Kaplan B. Evaluation of drug interaction software to identify alerts for transplant medications. Ann Pharmacother 2005; 39: 45-50.